WebOct 25, 2024 · LONDON--(BUSINESS WIRE)-- The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that seven biopharmaceutical industry partners together with the Loulou Foundation have formed a pre-competitive consortium … WebAug 25, 2024 · He has sponsored research agreements with Amicus Therapeutics, Biogen, Elaaj Bio, FA212, G2 Bio, G2 Bio-associated asset companies, iECURE, Janssen, Passage Bio, and Scout Bio, which are licensees of University of Pennsylvania technology. J.M.W. and J.J.S. are inventors on patents/patents filed by the University of Pennsylvania.
Passage Bio, Inc. - Investors and News - Financials and Filings
http://www.draccon.com/dracaena-report/cdkl5forum2024#:~:text=The%20gene%20therapy%20program%20from%20Penn%2FElaaj%20came%20with,deficiency%20that%20get%20corrected%20with%20the%20gene%20therapy. WebMar 24, 2024 · Introductory Paragraph. Efforts to improve liver gene therapy have focused on next-generation adeno-associated virus (AAV) vector capsids, transgene delivery, … bolsonaro coup 2022
CRISPR/Cas9 directed to the Ube3a antisense transcript …
WebJan 18, 2024 · The seven companies are Amicus Therapeutics; Biogen Inc.; Elaaj Bio; Marinus Pharmaceuticals Inc.; PTC Therapeutics; Ultragenyx Pharmaceutical Inc.; and Zogenix, Inc. Also, several agents with novel mechanisms of action are keenly being reconnoitered in ongoing clinical trials. Similarly, an initiative from several other countries … WebLoulou Foundation is a private non-profit UK foundation dedicated to advancing research into the understanding and development of therapeutics for CDKL5 deficiency disorder. … WebBiogen, Elaaj Bio, FA212, Janssen, Moderna, Passage Bio, Regeneron, Scout Bio, Surmount Bio, and Ultragenyx, which are licensees of Penn technology. JMW is an inventor on patents that have been licensed to various biopharmaceutical companies and for which he may receive payments. bolsonaro comer indio